Renowned Myeloma Expert Joins Mount Sinai

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.

Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai (ISMM), one of the elite cancer centers designated by the National Cancer Institute (NCI). Dr. Barlogie will serve as director of research in the Myeloma Program led by Sundar Jagannath, MD, Professor of Hematology and Medical Oncology at ISMM.

“We are extremely excited for Dr. Barlogie to join us as he brings a wealth of expertise and innovation in myeloma research,” said Steven Burakoff, MD, Lillian and Henry M. Stratton Professor of Cancer Medicine and Director of The Tisch Cancer Institute at Mount Sinai. “With him and Dr. Jagannath at the helm, Mount Sinai will have the country’s premier myeloma program.”

"I am thrilled to join Mount Sinai and collaborate once again with my good friend and colleague, Dr. Sundar Jagannath,” said Dr. Barlogie. “I am excited to collaborate with Sundar and other elite scientists to find novel approaches for patients with high-risk myeloma. We have a unique opportunity to move the field forward, and our understanding of the underlying mechanisms in the transition to malignant disease.”

Dr. Barlogie's work has focused on biological and therapeutic research, including chemotherapy, immunotherapy and hematopoietic stem cell transplantation. Among his seminal contributions are the developments of the VAD regimen for refractory myeloma, autologous stem cell supported high dose therapy, tandem transplants, and thalidomide. Many new biological insights have been gained through Dr. Barlogie’s research, notably the identification of chromosome 13 deletions as a separate high-risk entity in myeloma, and more recently, the identification of distinct risk-stratified subgroups of myeloma.

Prior to joining Mount Sinai, Dr. Barlogie served for 20 years as director of Myeloma Institute for Research & Therapy at University of Arkansas for Medical Sciences (UAMS) and institute he founded. Under his leadership, the Institute became a world-renowned program and was recently awarded a $10 million grant to create the Bart Barlogie Center for Molecular Diagnostics and the Celgene Distinguished Endowed Chair in Molecular Therapeutics at UAMS.

Dr. Barlogie was educated in Germany and earned his post-graduate degrees at Heidelberg University and the Max Planck Institute for Medical Research. Following residency at the Universities of Munich and Muenster, he joined MD Anderson Hospital and Tumor Research Institute as a fellow. Dr. Barlogie's initial laboratory investigation was dedicated to studying tumor cell cycle kinetics and its implications for designing combination chemotherapy.

Dr. Barlogie is a Fellow of the American College of Physicians and has served on the Board of Directors of the International Myeloma Foundation. He has received numerous honors including the prestigious Jan Waldenstrom Award, the Celgene Career Achievement Award in Hematology Research, a Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, and the National Physician of the Year award for Clinical Excellence from Castle Connolly Medical Ltd.

Dr. Barlogie has published extensively, including more than 526 peer reviewed journal articles including four in the New England Journal of Medicine and 75 book chapters. He currently serves on the editorial boards of Annals of Hematology, Blood, Clinical and Experimental Medicine, Clinical Cancer Research, Clinical Lymphoma & Myeloma, Current Cancer Therapy Reviews, Clinical Myeloma, International Journal of Clinical Oncology, Oncologie and The Oncologist.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 minority-owned free-standing ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. Seven departments at The Mount Sinai Hospital and one at the New York Eye and Ear Infirmary (NYEE) ranked nationally in the top 25 in the 2015-2016 “Best Hospitals” issue of U.S. News & World Report. Mount Sinai’s Kravis Children’s Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.